Duration of Dual Antiplatelet Therapy Following Drug-Eluting Stent Implantation in Diabetic and Non-Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
暂无分享,去创建一个
Samin K. Sharma | C. Lavie | G. Helft | G. Stefanini | R. Waksman | D. Mukherjee | S. Elmariah | F. Feres | Abhishek Sharma | A. Vallakati | J. Marmur | D. Drachman | A. Garg | C. Obiagwu | R. Waksman
[1] C. Lavie,et al. Duration of Dual Antiplatelet Therapy Following Drug-Eluting Stent Implantation: A Systematic Review and Meta-analysis of Randomized Controlled Trials. , 2017, Current problems in cardiology.
[2] Jason E. Moore,et al. Enteric Coating and Aspirin Nonresponsiveness in Patients With Type 2 Diabetes Mellitus. , 2017, Journal of the American College of Cardiology.
[3] Antonio Colombo,et al. Short term versus long term dual antiplatelet therapy after implantation of drug eluting stent in patients with or without diabetes: systematic review and meta-analysis of individual participant data from randomised trials , 2016, British Medical Journal.
[4] Samin K. Sharma,et al. Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Patients With and Without Acute Coronary Syndrome: A Systematic Review of Randomized Controlled Trials. , 2016, Mayo Clinic proceedings.
[5] Samin K. Sharma,et al. Duration of dual antiplatelet therapy after various drug-eluting stent implantation. , 2016, International journal of cardiology.
[6] J. Spertus,et al. Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. , 2016, JAMA.
[7] Y. Hayashi,et al. Antiplatelet therapy discontinuation and stent thrombosis after sirolimus-eluting stent implantation: five-year outcome of the j-Cypher Registry. , 2015, International journal of cardiology.
[8] E. Vicaut,et al. Stopping or continuing clopidogrel 12 months after drug-eluting stent placement: the OPTIDUAL randomized trial. , 2015, European heart journal.
[9] Seung‐Jung Park,et al. Duration of Dual Antiplatelet Therapy After Coronary Stenting: A Review of the Evidence. , 2015, Journal of the American College of Cardiology.
[10] G. Stone,et al. Long-Term Safety of Drug-Eluting and Bare-Metal Stents: Evidence From a Comprehensive Network Meta-Analysis. , 2015, Journal of the American College of Cardiology.
[11] Giuseppe Biondi-Zoccai,et al. Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials , 2015, The Lancet.
[12] Walter Desmet,et al. ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting. , 2015, European heart journal.
[13] G. Lip,et al. Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials , 2015, BMJ : British Medical Journal.
[14] Samin K. Sharma,et al. Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials. , 2015, Journal of the American College of Cardiology.
[15] L. Mauri,et al. Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis , 2015, The Lancet.
[16] A. Jaffe,et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.
[17] Braunwald,et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. , 2014, The New England journal of medicine.
[18] E. Vicaut,et al. Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial , 2014, The Lancet.
[19] G. Grunwald,et al. Mortality after presentation with stent thrombosis is associated with time from index percutaneous coronary intervention: a report from the VA CART program. , 2014, American heart journal.
[20] E. Grove,et al. The influence of type 2 diabetes on fibrin clot properties in patients with coronary artery disease , 2014, Thrombosis and Haemostasis.
[21] E. Herzog,et al. Meta-analysis of randomized clinical trials comparing short-term versus long-term dual antiplatelet therapy following drug-eluting stents. , 2014, The American journal of cardiology.
[22] M. Jeong,et al. Optimal Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation: A Randomized, Controlled Trial , 2014, Circulation.
[23] Deepak L. Bhatt,et al. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. , 2013, JAMA.
[24] P. Serruys,et al. Long-term outcome of the unrestricted use of everolimus-eluting stents compared to sirolimus-eluting stents and paclitaxel-eluting stents in diabetic patients: the Bern-Rotterdam diabetes cohort study. , 2013, International journal of cardiology.
[25] M. Joner,et al. Incidence and predictors of restenosis after coronary stenting in 10 004 patients with surveillance angiography , 2013, Heart.
[26] Y. Jang,et al. A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). , 2012, Journal of the American College of Cardiology.
[27] Deepak L. Bhatt,et al. Short- and Long-Term Outcomes With Drug-Eluting and Bare-Metal Coronary Stents: A Mixed-Treatment Comparison Analysis of 117 762 Patient-Years of Follow-Up From Randomized Trials , 2012, Circulation.
[28] O. Boutaud,et al. Suboptimal Inhibition of Platelet Cyclooxygenase-1 by Aspirin in Metabolic Syndrome , 2012, Hypertension.
[29] Marc P. Bonaca,et al. American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 trial (Trial to Assess Improvement in Therape , 2012, Circulation.
[30] M. Jeong,et al. Six-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents: The Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) Randomized, Multicenter Study , 2012, Circulation.
[31] Jeroen J. Bax,et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). , 2011, European heart journal.
[32] D. Angiolillo,et al. Diabetes and Antiplatelet Therapy in Acute Coronary Syndrome , 2011, Circulation.
[33] O. Deveci,et al. Aspirin resistance is associated with glycemic control, the dose of aspirin, and obesity in type 2 diabetes mellitus. , 2010, The Journal of clinical endocrinology and metabolism.
[34] D. Moher,et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement , 2009, BMJ : British Medical Journal.
[35] I. Liu,et al. Long-term outcomes by clopidogrel duration and stent type in a diabetic population with de novo coronary artery lesions. , 2008, Journal of the American College of Cardiology.
[36] J. Badimón,et al. Baseline platelet activity and response after clopidogrel in 257 diabetics among 822 patients with coronary artery disease , 2008, Thrombosis and Haemostasis.
[37] P. Gurbel,et al. The Effect of Aspirin Dosing on Platelet Function in Diabetic and Nondiabetic Patients , 2007, Diabetes.
[38] P. Serruys,et al. Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.
[39] I. Iakovou,et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. , 2005, JAMA.
[40] C. Davidson,et al. Diabetes and coronary revascularization. , 2005, JAMA.
[41] W. O’Neill,et al. Impact of Sirolimus-Eluting Stents on Outcome in Diabetic Patients: A SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) Substudy , 2004, Circulation.
[42] J. Beckman,et al. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I , 2013, European heart journal.
[43] V. Fuster,et al. Blood thrombogenicity in type 2 diabetes mellitus patients is associated with glycemic control. , 2001, Journal of the American College of Cardiology.
[44] M. Bourassa,et al. Management of coronary artery disease: therapeutic options in patients with diabetes. , 2000, Journal of the American College of Cardiology.
[45] T. B. Investigators,et al. Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI) , 1997, Circulation.
[46] Deepak L. Bhatt,et al. Short- versus long-term dual antiplatelet therapy after drug-eluting stent implantation: an individual patient data pairwise and network meta-analysis. , 2015, Journal of the American College of Cardiology.